Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32 nd Annual Healthcare Conference
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol ( LDL-C ) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides ( > 500 mg/dL) Results Support
Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association’s Virtual Scientific Sessions 2020
Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effective ness in reducing major adverse cardiovascular events (MACE) in studied high-risk patients Breadth of scientific evidence presented provides further insight into the unique ,
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association’s Virt
VASCEPA ® , compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a history of CABG by 2 4% and 3 6 %, respectively, and key secondary composite first hard MACE, comprised of
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in
The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction
Wang X, Verma S, Mason RP, Bhatt DL. The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Curr Diabetes Rep. 2020;20:65.